Abstract Objective: While using a transcutaneous system for assessment of liver function by indocyanine green plasma disappearance rate (ICG-PDR) in critically ill patients, we compared the agreement between ICG-PDR obtained by the recommended standard ICG dosage (0.5 mg/kg) and a reduced dosage (0.25 mg/kg). Design: Clinical study. Setting: Intensive care unit of a university hospital. Patients: Critically ill patients (n=16, 5 female, 11 male) who underwent liver function monitoring by ICG-PDR for clinical indication. Measurements and results: We analyzed 31 pairs of ICG-PDR measurements by applying the recommended dosage (0.5 mg/kg, ICG-PDR 0.5 ) and a reduced dosage (0.25 mg/kg, ICG-PDR 0.25 ). For each comparative measurement either first 0.5 mg/kg or 0.25 mg/kg of ICG was injected in a random fashion and followed by the corresponding dosage 60 min later. All patients were sedated and mechanically ventilated via a tracheal tube. Each patient was monitored by an ICG finger clip which was connected to a liver function monitoring system (LiMon, Pulsion Medical Systems, Germany). ICG-PDR 0.25 was 2.7-25.0 %/min and ICG-PDR 0.5 4.5-24.5 %/min, respectively. Linear regression analysis revealed ICG-PDR 0.25 = 1.13·ICG-PDR 0.5 0.66 %/min (r=0.95, p<0.0001) with a mean bias 1.0 %/min (standard deviation 2.5 %/min). The 15 min residual rates were also highly correlated (r=0.92, p<0.0001) with a mean bias of 0.3%. Conclusion: A reduced dosage of ICG (0.25 mg/kg) is sufficiently accurate for transcutaneous measurement of ICG-PDR in critically ill patients.
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Introduction
Monitoring of regional organ blood flow and function is often crucial for guiding therapy in critically ill patients and has been highly recommended. However, particularly monitoring of liver perfusion and function is characterized by various limitations, and the indocyanine green plasma disappearance rate (ICG-PDR) has been suggested more recently [1, 2] . After venous injection, indocyanine green (ICG) is nearly completely eliminated unchanged by the liver into the bile without entero-hepatic recirculation. In principle, elimination of ICG from the blood is determined by several factors: hepatic blood flow, cellular uptake, and excretion into the bile. Previously, we showed that transcutaneous measurement of ICG-PDR is accurate when compared to an arterial fiber-optic system [3] . The major advantage of the transcutaneous system is that it enables assessment of liver function non-invasively in critically ill patients. Nevertheless, using a dosage of 0.5 mg/kg ICG is associated with considerable costs. Moreover, cost reduction would thus be desirable by using an amount of ICG as low as possible which still yields reliable measurement of ICG-PDR. In this study, we analyzed the agreement between ICG-PDR measured with the recommended dosage (0.5 mg/kg) and a reduced dosage (0.25 mg/kg).
Patients and methods
The study was approved by the local ethics committee. We studied and analyzed data from 16 critically ill patients of an operative intensive care unit. All patients underwent monitoring of ICG-PDR for clinical indication. Patients' characteristics are presented in Table 1 . Each patient received an ICG finger clip which was connected to liver function monitor (LiMon, Pulsion Medical Systems, Germany). In these 16 patients, 31 measurements were obtained (range 1-3 measurements in each patient). For each comparative measurement either first 0.5 mg/kg ICG (Pulsion Medical Systems, Munich, Germany) or a reduced dosage of 0.25 mg/kg was injected in a random fashion 60 min later through a central venous catheter. Respirator settings and dosages of vasoactive drugs remained unchanged during the study. No N-acetylcystein or other drugs which may influence hepatic blood flow were administered during the study period. There were no changes in fluid status and central venous pressure was unchanged at the two time points. The patients did not receive enteral feeding during the study period.
Data analysis
All results are expressed as mean and standard deviation. The relationship between ICG-PDR 0.25 and ICG-PDR 0.5 and between the respective 15 min ICG residual rates was analyzed by linear regression. The agreement between ICG-PDR 0.25 and ICG-PDR 0.5 was analyzed according to Bland-Altman. Statistical analysis was performed using software SigmaStat for Windows (version 1.0). A p-value less than 0.05 was considered significant. (Fig. 1) . Furthermore, BlandAltman analysis showed a trend towards lower percentage differences between both dosages with higher ICG-PDR (mean percentage difference 2.1%). The 15 min residual rates (range 2.4-66.7 % for ICG-PDR 0.25 vs. 2.5-50.9 % for ICG-PDR 0.5 ) derived from the two ICG dosages were also highly correlated (r=0.92, p<0.0001) with a mean bias of 0.3%.
Discussion
In this study, we compared two dosages of ICG (0.5 mg/ kg vs. 0.25 mg/kg) for the transcutaneous measurement of indocyanine green plasma disappearance rate (ICG-PDR) in critically ill patients with mechanical ventilation and vasoactive drug support. In our results, we found that the lower dosage of ICG (0.25 mg/kg) is sufficiently accurate for the measurement of ICG-PDR.
In general, the clinical value of the ICG-PDR has already been demonstrated in various studies. In liver transplantation, ICG-PDR may be used for evaluation of donor organs as it has been found that successful transplantation was correlated with organ function: poor liver function as measured by ICG-PDR was associated with higher rates of discarded grafts. A borderline value for ICG-PDR of 15%/min was identified. Krenn et al. [4] 1  f  65  158  66  36  23  5  2  m  82  174  74  24  14  10  3  m  84  160  70  33  15  5  4  m  81  168  70  85  32  13  5  m  71  168  88  40  32  4  6  f  85  162  80  71  27  5  7  f  51  175  90  31  25  5  8  m  53  180  85  40  16  7  9  m  76  180  90  37  16  6  10  m  63  180  95  44  18  8  11  m  55  172  100  55  27  14  12  f  86  163  55  71  34  10  13  m  60  175  56  34  20  9 have shown the utility of ICG-clearance as an immediate and early test on graft function after liver transplantation. Furthermore, ICG-PDR has been compared with different variables of liver function in potential candidates for hepatic transplantation in adult and pediatric patients. ICG half-life was ascribed to be the best predictor of prognosis but also within the different groups of liver cirrhosis. Other parameters, such as serum bilirubin, albumin and cholinesterase, or the Child-Pugh score, were found to be inappropriate for assessing short-term prognosis in cirrhosis independent of the etiology of the underlying liver disease. Furthermore, ICG-PDR has been shown to be highly correlated with outcome in critically ill patients [1, 2, 5] . The prognostic properties of ICG-PDR as one single organ parameter were comparable or even superior to more complex scores (APACHE II, SAPS II) [1] . Kimura et al. [5] published the first study analyzing sequential measurements in patients with septic shock. The authors concluded that ICG-PDR can identify reversible liver injury in sepsis as an indicator of good prognosis. Either failure to increase ICG-PDR within 120 h or an extremely low ICG-PDR <5%/min was identified as a poor prognostic sign.
Furthermore, ICG-PDR is regarded to be of significant value for liver surgery, since the extent of resection can be determined appropriately. Hashimoto and Watanabe [6] quantified hepatic cellular volume with CT-scan and computer-aided image analysis and found it to be proportional with ICG-PDR in patients scheduled for liver resection. Among a variety of standard liver function parameters or tests, no other preoperative test than ICG clearance has been ascribed to be useful in determining the outcome of resection in patients with cirrhosis and a cut-off value for ICG clearance had been determined below which hepatic resection should not be attempted.
In principle, hepatic function as assessed by ICG-PDR per se is influenced by the level of post-expiratory pressure (PEEP) as has been shown in an animal experimental setting using positive pressure ventilation. ICG extraction was found to increase with an increase in PEEP and reversed to baseline after withdrawal of PEEP. As explanation, an increased plasma movement resulting in a higher trans-sinusoidal ICG passage into the extracellular space of the liver, and thus an increased uptake due to higher backpressure to hepatic outflow, were discussed. To exclude any influence of airway pressures on the comparison between the different ICG dosages, PEEP and other respirator settings were kept constant during our study. As also vasoactive drugs [7, 8] or Nacetyl-cystein (NAC) [9] may change ICG-PDR, we did not change dosages of vasoactive drugs or administer NAC during the study. Furthermore, since it is known to influence hepato-splanchnic blood flow, patients did not receive enteral feeding during the study period.
ICG kinetics may change rather rapidly. One limitation of our study which is impossible to overcome is that we assessed ICG-PDR at two different time points while using two dosages of ICG. In this study, we considered a time span between the two measurements of 60 min to be appropriate. In general, as we could show in a previous work, there is spontaneous variability in splanchnic blood flow in critically ill patients [10] . However, as a consequence, we cannot exclude that differences in ICG-PDR between the two time points were related to actual changes in hepatic blood flow and not as a result of the disagreement between of the two measurements (ICG-PDR 0.5 vs. ICG-PDR 0.25 ). To reduce this source of error, we applied a random mode for the sequence of ICG-PDR measurement: either first 0.5 mg/kg or 0.25 mg/kg of ICG was injected before the respective corresponding dosage was injected for the measurement of ICG-PDR.
Although the technology of pulse densitometry for transcutaneous measurement of ICG has been developed several years ago, a new device has recently been introduced into the clinical setting. We previously reported the agreement between invasive arterial (fiberoptic-based) and transcutaneous (pulse densitometry) Fig. 1 Linear regression analysis (95% confidence intervals, regression line bold) and BlandAltman plot for the comparison between ICG-PDR 0.5 (0.5 mg/ kg) and ICG-PDR 0.25 (0.25 mg/ kg) derived indocyanine-green plasma disappearance rate in 16 critically ill patients assessment of the ICG-PDR in critically ill patients [3] . Thus, ICG-PDR can be monitored reliably by a noninvasive system. Currently, resources in health care systems are becoming reduced and, in addition to patient safety, cost reduction due to a lower amount of ICG is considered desirable. We found that a reduced dosage of ICG still allows accurate measurement of ICG-PDR. Since the amount of ICG can be halved, one may save approximately 23 e per ICG-PDR measurement in a 70 kg patient. For the future, transcutaneous assessment of liver function by ICG-PDR seems to be a promising clinical tool, even more so since a reduced dosage of ICG (0.25 mg/kg) was found to be reliable for the measurement of ICG-PDR.
Conclusion
A reduced dosage of ICG (0.25 mg/kg) is sufficiently accurate for transcutaneous measurement of ICG-PDR in critically ill patients.
